Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13416-13433

  Schumann, Tim ^a   Adhikary, Till ^a   Wortmann, Annika ^a   Finkernagel, Florian ^a   Lieber, Sonja ^a   Schnitzer, Evelyn ^a   Legrand, Nathalie ^a   Schober, Yvonne ^a   Nockher, W Andreas ^a   Toth, Philipp M ^a   Diederich, Wibke E ^a   Nist, Andrea ^a   Stiewe, Thorsten ^a   Wagner, Uwe ^b   Reinartz, Silke ^b   Müller Brüsselbach, Sabine ^a   Müller, Rolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Fachbereich Medizin der Universitat Marburg   (Germany)

Author keywords

ANGPTL4; Linoleic acid; Ovarian carcinoma; PPAR ; Tumor associated macrophages

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; CD300A ANTIGEN; FAT DROPLET; FATTY ACID; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LYMPHOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; POLYUNSATURATED FATTY ACID; TRANSCRIPTOME; UNCLASSIFIED DRUG; LIGAND;

ADULT; ANGPTL4 GENE; ARTICLE; ASCITES; CD300A GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIPID STORAGE; LIPIDOMICS; LRP5 GENE; MACROPHAGE; MAP3K8 GENE; MONOCYTE; OVARY CANCER; POLARIZATION; PPARDELTA GENE; RECURRENCE FREE SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; CASE-CONTROL STUDIES; FATTY ACIDS; FEMALE; HUMANS; LIGANDS; LINOLEIC ACID; MACROPHAGES; MICE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PPAR DELTA; PPAR-BETA; TUMOR MICROENVIRONMENT;

EID: 84931044554     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3826     Document Type: Article

References (62)

1. Condeelis J and Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124:263-266.
2. Hagemann T, Biswas SK, Lawrence T, Sica A and Lewis CE. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood. 2009; 113:3139-3146.
3. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4:71-78.
4. Sica A and Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122:787-795.
5. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12:253-268.
6. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40:274-288.
7. Qian BZ and Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141:39-51.
8. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S and Muller R. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014; 134:32-42.
9. Kostadinova R, Wahli W and Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem. 2005; 12:2995-3009.
10. Wahli W and Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012; 23:351-363.
11. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD and Gonzalez FJ. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol. 2000; 20:5119-5128.
12. Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, Goh YY, Wahli W, Michalik L and Tan NS. Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing. J Cell Biol. 2009; 184:817-831.
13. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B and Lee CH. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008; 7:485-495.
14. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, Subramanian V, Mukundan L, Ferrante AW and Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 2008; 7:496-507.
15. Peters JM, Shah YM and Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012; 12:181-195.
16. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA and Milburn MV. Molecular recognition of fatty acids by peroxisome proliferatoractivated receptors. Mol Cell. 1999; 3:397-403.
17. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM and Dey SK. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. 1999; 13:1561-1574.
18. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Müller-Brüsselbach S and Müller R. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor β/δ agonist. Mol Pharmacol. 2010; 77:171-184.
19. Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, Scharfe M, Jarek M, Blöcker H, Müller-Brüsselbach S and Müller R. Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). PLoS One. 2011; 6:e16344.
20. Naruhn S, Toth PM, Adhikary T, Kaddatz K, Pape V, Dörr S, Klebe G, Müller-Brüsselbach S, Diederich WE and Müller R. High-affinity peroxisome proliferator-activated receptor beta/delta-specific ligands with pure antagonistic or inverse agonistic properties. Mol Pharmacol. 2011; 80:828-838.
21. Adhikary T, Brandt DT, Kaddatz K, Stockert J, Naruhn S, Meissner W, Finkernagel F, Obert J, Lieber S, Scharfe M, Jarek M, Toth PM, Scheer F, Diederich WE, Reinartz S, Grosse R, et al. Inverse PPARbeta/delta agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. Oncogene. 2013; 32:5241-5252.
22. Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, Maemura K, Kubota N, Kadowaki T and Nagai R. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat Med. 2008; 14:656-666.
23. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM and Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 2003; 302:453-457.
24. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC and Vazquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005; 65:832-841.
25. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, Jensen UB, Schroder HD, Staels B, Iversen L, Bolund L, Kragballe K and Kristiansen K. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol. 2003; 121:1104-1117.
26. Ding G, Cheng L, Qin Q, Frontin S and Yang Q. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol. 2006; 40:821-828.
27. Stockert J, Wolf A, Kaddatz K, Schnitzer E, Finkernagel F, Meissner W, Müller-Brüsselbach S, Kracht M and Müller R. Regulation of TAK1/TAB1-Mediated IL-1beta Signaling by Cytoplasmic PPARbeta/delta. PLoS One. 2013; 8:e63011.
28. Adhikary T, Wortmann A, Schumann T, Finkernagel F, Lieber S, Roth K, Toth PM, Diederich WE, Nist A, Stiewe T, Kleinesudeik L, Reinartz S, Müller-Brüsselbach S and Müller R. The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state. Nucl Acids Res. 2015:in press.
29. Yamashiro S, Takeya M, Nishi T, Kuratsu J, Yoshimura T, Ushio Y and Takahashi K. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol. 1994; 145:856-867.
30. Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R and Kunz-Schughart LA. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol. 2003; 33:1311-1320.
31. Murdoch C, Giannoudis A and Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004; 104:2224-2234.
32. Ahmed N and Stenvers KL. Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research. Front Oncol. 2013; 3:256.
33. Degenhardt T, Saramaki A, Malinen M, Rieck M, Vaisanen S, Huotari A, Herzig KH, Müller R and Carlberg C. Three Members of the Human Pyruvate Dehydrogenase Kinase Gene Family Are Direct Targets of the Peroxisome Proliferator-activated Receptor β/δ. J Mol Biol. 2007.
34. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
35. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR and Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008; 133:66-77.
36. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK and DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A. 2000; 97:13275-13280.
37. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR and Palmer CN. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem. 2001; 276:44258-44265.
38. Caselmann WH and Jungst D. Isolation and characterization of a cellular protein-lipid complex from ascites fluid caused by various neoplasms. Cancer Res. 1986; 46:1547-1552.
39. Yam D, Ben-Hur H, Dgani R, Fink A, Shani A and Berry EM. Subcutaneous, omentum and tumor fatty acid composition, and serum insulin status in patients with benign or cancerous ovarian or endometrial tumors. Do tumors preferentially utilize polyunsaturated fatty acids? Cancer Lett. 1997; 111:179-185.
40. Gansler TS, Hardman W, 3rd, Hunt DA, Schaffel S and Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997; 28:686-692.
41. Tania M, Khan MA and Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010; 17:6-11.
42. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K and Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17:1498-1503.
43. Fraser DA, Thoen J, Rustan AC, Forre O and Kjeldsen-Kragh J. Changes in plasma free fatty acid concentrations in rheumatoid arthritis patients during fasting and their effects upon T-lymphocyte proliferation. Rheumatology (Oxford). 1999; 38:948-952.
44. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Muller M and Kersten S. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem. 2006; 281:934-944.
45. Kaddatz K, Adhikary T, Finkernagel F, Meissner W, Müller-Brüsselbach S and Müller R. Transcriptional profiling identifies functional interactions of TGFβ and PPARβ/δ signaling: synergistic induction of ANGPTL4 transcription. J Biol Chem. 2010; 285:29469-29479.
46. Zhu P, Goh YY, Chin HF, Kersten S and Tan NS. Angiopoietin-like 4: a decade of research. Biosci Rep. 2012; 32:211-219.
47. Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M and Perou CM. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009; 7:9.
48. Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, Lam CR, Boukamp P, Pan JY, Tan SH, Kersten S, Li HY, Ding JL and Tan NS. Angiopoietin-like 4 Protein Elevates the Prosurvival Intracellular O(2)(-):H(2)O(2) Ratio and Confers Anoikis Resistance to Tumors. Cancer Cell. 2011; 19:401-415.
49. Tanaka T, Tahara-Hanaoka S, Nabekura T, Ikeda K, Jiang S, Tsutsumi S, Inagaki T, Magoori K, Higurashi T, Takahashi H, Tachibana K, Tsurutani Y, Raza S, Anai M, Minami T, Wada Y, et al. PPARbeta/delta activation of CD300a controls intestinal immunity. Sci Rep. 2014; 4:5412.
50. Higuchi Y, Setoguchi M, Yoshida S, Akizuki S and Yamamoto S. Enhancement of c-fos expression is associated with activated macrophages. Oncogene. 1988; 2:515-521.
51. Wiezlak M, Diring J, Abella J, Mouilleron S, Way M, McDonald NQ and Treisman R. G-actin regulates the shuttling and PP1 binding of the RPEL protein Phactr1 to control actomyosin assembly. J Cell Sci. 2012; 125:5860-5872.
52. Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, Ma F and Jiang B. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012; 11:23.
53. Lee D, Lee HS, Yang SJ, Jeong H, Kim DY, Lee SD, Oh JW, Park D and Kim MG. PRSS14/Epithin is induced in macrophages by the IFN-gamma/JAK/STAT pathway and mediates transendothelial migration. Biochem Biophys Res Commun. 2011; 405:644-650.
54. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP and He X. LDLreceptor- related proteins in Wnt signal transduction. Nature. 2000; 407:530-535.
55. Borrell-Pages M, Romero JC, Juan-Babot O and Badimon L. Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages. Eur Heart J. 2011; 32:2841-2850.
56. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G and Brugge JS. Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes Dev. 2011; 25:1716-1733.
57. Toth PM, Naruhn S, Pape VF, Dörr SM, Klebe G, Müller R and Diederich WE. Development of Improved PPARbeta/ delta Inhibitors. ChemMedChem. 2012; 7:159-170.
58. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R and Evans RM. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A. 2002; 99:303-308.
59. Hayashi S, Lewis P, Pevny L and McMahon AP. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech Dev. 2002; 119 Suppl 1:S97-S101.
60. Scholtysek C, Katzenbeisser J, Fu H, Uderhardt S, Ipseiz N, Stoll C, Zaiss MM, Stock M, Donhauser L, Bohm C, Kleyer A, Hess A, Engelke K, David JP, Djouad F, Tuckermann JP, et al. PPARbeta/delta governs Wnt signaling and bone turnover. Nat Med. 2013:19.
61. Jérôme V and Müller R. Tissue-specific, cell cycleregulated chimeric transcription factors for the targeting of gene expression to tumor cells. Hum Gene Ther. 1998; 9:2653-2659.
62. Gyorffy B, Lanczky A and Szallasi Z. Implementing an online tool for genome-wide validation of survivalassociated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19:197-208.